452 related articles for article (PubMed ID: 21198671)
1. Influenza vaccine immunology.
Dormitzer PR; Galli G; Castellino F; Golding H; Khurana S; Del Giudice G; Rappuoli R
Immunol Rev; 2011 Jan; 239(1):167-77. PubMed ID: 21198671
[TBL] [Abstract][Full Text] [Related]
2. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.
Brett IC; Johansson BE
Virology; 2005 Sep; 339(2):273-80. PubMed ID: 15996702
[TBL] [Abstract][Full Text] [Related]
3. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
4. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
5. Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines.
Settembre EC; Dormitzer PR; Rappuoli R
J Mol Cell Biol; 2011 Jun; 3(3):144-6. PubMed ID: 21430014
[TBL] [Abstract][Full Text] [Related]
6. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
Caillet C; Piras F; Bernard MC; de Montfort A; Boudet F; Vogel FR; Hoffenbach A; Moste C; Kusters I
Vaccine; 2010 Apr; 28(18):3076-9. PubMed ID: 20193791
[TBL] [Abstract][Full Text] [Related]
7. Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination.
Subbramanian RA; Basha S; Shata MT; Brady RC; Bernstein DI
Vaccine; 2010 Dec; 28(52):8258-67. PubMed ID: 21050903
[TBL] [Abstract][Full Text] [Related]
8. Immunology. Prime, boost, and broaden.
Doms RW
Science; 2010 Aug; 329(5995):1021-2. PubMed ID: 20798304
[No Abstract] [Full Text] [Related]
9. How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.
Rudraraju R; Mordant F; Subbarao K
J Infect Dis; 2019 Apr; 219(Suppl_1):S81-S87. PubMed ID: 30715386
[No Abstract] [Full Text] [Related]
10. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
11. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
[TBL] [Abstract][Full Text] [Related]
12. Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains.
Lee VJ; Tay JK; Chen MI; Phoon MC; Xie ML; Wu Y; Lee CX; Yap J; Sakharkar KR; Sakharkar MK; Lin RT; Cui L; Kelly PM; Leo YS; Tan YJ; Chow VT
Vaccine; 2010 Oct; 28(42):6852-7. PubMed ID: 20723626
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.
Crowe BA; Brühl P; Gerencer M; Schwendinger MG; Pilz A; Kistner O; Koelling-Schlebusch K; Aichinger G; Singer J; Zeitlinger M; Müller M; Ehrlich H; Barrett PN
Vaccine; 2010 Dec; 29(2):166-73. PubMed ID: 21055500
[TBL] [Abstract][Full Text] [Related]
14. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
Johansson BE; Kilbourne ED
Virology; 1996 Nov; 225(1):136-44. PubMed ID: 8918540
[TBL] [Abstract][Full Text] [Related]
15. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
Plennevaux E; Blatter M; Cornish MJ; Go K; Kirby D; Wali M; Reeves-Hoché MK; Denis M
Vaccine; 2011 Feb; 29(8):1569-75. PubMed ID: 21219979
[TBL] [Abstract][Full Text] [Related]
16. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.
Hancock K; Veguilla V; Lu X; Zhong W; Butler EN; Sun H; Liu F; Dong L; DeVos JR; Gargiullo PM; Brammer TL; Cox NJ; Tumpey TM; Katz JM
N Engl J Med; 2009 Nov; 361(20):1945-52. PubMed ID: 19745214
[TBL] [Abstract][Full Text] [Related]
17. Single dose of oil-adjuvanted inactivated vaccine protects chickens from lethal infections of highly pathogenic H5N1 influenza virus.
Hwang SD; Kim HS; Cho SW; Seo SH
Vaccine; 2011 Mar; 29(11):2178-86. PubMed ID: 21172378
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
[TBL] [Abstract][Full Text] [Related]
19. Trends in development of the influenza vaccine with broader cross-protection.
Stropkovská A; Janulíková J; Varecková E
Acta Virol; 2010; 54(1):7-19. PubMed ID: 20201609
[TBL] [Abstract][Full Text] [Related]
20. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function.
Sambhara S; Kurichh A; Miranda R; Tumpey T; Rowe T; Renshaw M; Arpino R; Tamane A; Kandil A; James O; Underdown B; Klein M; Katz J; Burt D
Cell Immunol; 2001 Aug; 211(2):143-53. PubMed ID: 11591118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
